Abstract Coronavirus disease (COVID-19) is caused by the novel severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and is responsible for the ongoing 2019–2020 …

While acute respiratory infections are known to increase thrombosis risk [1], the incidence of
venous thromboembolic events (VTE) in patients with coronavirus disease 2019 (COVID-19) …

Abstract Purpose of Review Novel coronavirus disease 2019 (COVID-19) has been
associated with an increased risk of arterial and venous thromboembolic (VTE) diseases …

Background: Emerging evidence shows that coronavirus disease 2019 (COVID-19) is
commonly complicated by coagulopathy, and venous thromboembolism (VTE) is considered …

The acute respiratory illnesses caused by severe acquired respiratory syndrome corona
Virus-2 (SARS-CoV-2) is a global health emergency, involving more than 8.6 million people …

Despite thromboprophylaxis, patients with coronavirus disease 2019 (COVID‐19) exhibit
hypercoagulability and higher venous thromboembolic risk, although its real incidence is still …

Coronavirus disease 2019 (COVID-19) has caused a global pandemic in just a few months,
causing millions infected. Nearly 20% of COVID-19 patients present severe coagulation …

Background: Recent studies revealed a high prevalence of venous thromboembolism (VTE)
events in coronavirus disease 2019 (COVID-19) patients, especially in those who are …

Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
appear to be at increased risk for venous thromboembolism (VTE), especially if they become …

Introduction Venous thromboembolism (VTE) has been observed as a frequent complication
in patients with severe novel coronavirus disease 2019 (COVID-19) infection requiring …